| abstract |
(A) melagatran or a pharmaceutically acceptable derivative thereof; and (B) dexamethasone or a pharmaceutically acceptable derivative thereof, wherein each of components (A) and (B) is pharmaceutically acceptable. Combination products formulated with an adjuvant, diluent or carrier, and use of such combination products in the treatment of conditions involving disseminated intravascular coagulation are provided. |